Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 16/20 | 0.67 |
| ▸ | RAD52 | P43351 | 1/20 | 0.66 |
| ▸ | TTK | P33981 | 4/20 | 0.58 |
| ▸ | BRD4 | O60885 | 4/20 | 0.58 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.58 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | PRKCG | P05129 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.51 |
| ▸ | NEK4 | P51957 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203787 | 0.95 | PLK1 (0.74) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203461 | 0.91 | PLK1 (0.71) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203986 | 0.91 | PLK1 (0.71) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1202863 | 0.90 | PLK1 (0.67) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203349 | 0.90 | PLK1 (0.69) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1204132 | 0.89 | PLK1 (0.68) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203263 | 0.88 | PLK1 (0.67) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL3549824 | 0.88 | RAD52 (0.76) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203674 | 0.87 | PLK1 (0.66) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203784 | 0.87 | PLK1 (0.73) | PLK1RAD52TTKBRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279806-B | Organic electrode material and preparation method and application thereof | 西南大学 | 2023-10-17 | — | — | CN | claimed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | claimed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| CN-101560183-B | Method for preparing 5-bromo-2-methylpyridine | ZHEJIANG MED XINCHANG PHARM | 2011-02-02 | — | — | CN | claimed |
| CN-101560183-A | Method for preparing 5-bromo-2-methylpyridine | ZHEJIANG MEDICINE CO LTD (CN) | 2009-10-21 | — | — | CN | claimed |
| CN-101514184-A | Synthetic method of 5-bromo-2-methylpyridine | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2009-08-26 | — | — | CN | claimed |
| CN-100427468-C | Apparatus and method for separating 5-bromo-2-methyl pyridine isomer by intermittent rectification under vacuum | UNIV TIANJIN (CN) | 2008-10-22 | — | — | CN | claimed |
| CN-1850803-A | Apparatus and method for separating 5-bromo-2-methyl pyridine isomer by intermittent rectification under vacuum | UNIV TIANJIN (CN) | 2006-10-25 | — | — | CN | claimed |
| EP-2917181-B1 | HETEROARYL DERIVATIVES AND USES THEREOF | JACOBUS PHARMACEUTICAL COMPANY INC (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| EP-2493889-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2545055-B1 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-09 | — | — | EP | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| EP-0508445-A1 | 1-Arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0508393-A1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5155117-A | Hypotensive agents | G. D. SEARLE & CO. (US) | 1992-10-13 | — | — | US | disclosed |
| WO-1992016523-A1 | 5-ARYLHETEROARYLALKYL-1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0504888-A1 | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |
| CN-1032539-A | The Thienoimidazole derivatives that replaces, their preparation method contains their pharmaceutical preparation and they are as the application of gastric acid secretion inhibitor | HOECHST AG (DE) | 1989-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | PLK1 23/4885RAD52 1278/4885TTK 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.